How does Petrelintide work?
Next-generation amylin analog with stronger receptor binding and weekly dosing. Same pathway as Cagrilintide. In plain terms, Petrelintide is zealand Pharma's long-acting amylin analog (partnered with Roche). Phase 2 complete, Phase 3 planned for H2 2026. A competing once-weekly amylin analog, not a Novo or Cagrilintide successor. Mechanistic detail like this comes largely from preclinical and early research, the human picture is limited.
What people use it for
- Trial participants in obesity studies
- Educational reference for the next-generation amylin pathway
- Followers of Zealand Pharma's metabolic pipeline
References
- Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity — Zealand Pharma (press release via GlobeNewswire), March 5, 2026
- Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity — Roche (press release), March 5, 2026
- A Randomized, Double-Blind, Phase 2 Trial of Once-Weekly Petrelintide Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) — ClinicalTrials.gov, NCT06926842 (Sponsor: Zealand Pharma)
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Petrelintide
Last updated 2026-06-06.